Tumor necrosis factor–like cytokine 1A (TL1A)

Tumor necrosis factor–like cytokine 1A (TL1A, also known as TNFSF15) is a type II transmembrane protein that self-assembles into homotrimers and belongs to the TNF superfamily. It is produced by several immune cells including monocytes, macrophages, dendritic cells, T cells, and also by non-immune cells such as synovial fibroblasts and endothelial cells. TL1A mediates its biological effects by binding to death receptor 3 (DR3, a member of the TNFR superfamily) and the decoy receptor DcR3, triggering downstream activation of NF-κB and MAPK signaling pathways. This leads to increased production of pro-inflammatory cytokines and influences differentiation, proliferation, and activation of T helper cell subsets (Th1, Th2, Th9, Th17). Aberrant expression of TL1A is associated with multiple inflammatory and autoimmune diseases, making it a promising therapeutic target. Experimental drugs blocking TL1A are under investigation for their potential to treat conditions such as inflammatory bowel disease and rheumatoid arthritis, highlighting both the therapeutic promise and safety challenges of modulating this cytokine.

Other names

TNFSF15VEGITumor necrosis factor ligand superfamily member 15

Neutralization of TL1A to block its binding to DR3/DcR3, leading to reduced pro-inflammatory signaling and Th cell activation. Inhibition of TL1A-induced NF-κB and MAPK pathway activation, suppressing cytokine secretion and inflammatory responses.